ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4

Figure 5

ARV-825 displays antitumor efficacy in the BRD4-NUT 3T3 xenograft model. (a) Diagram of xenograft flowchart, nude mice bearing xenograft tumors were treated by either 10 mg/kg ARV-825 or vehicle control intraperitoneally every day for 21 days. Data are the mean ± SEM (n = 6). (b) Mice body mass was weighed every 3 days. (c) Tumor volume was recorded every 3 days and calculated using the formula: (width × width × length × 0.52). (d) Photograph of xenograft tumors from ARV-825-or vehicle-treated mice. (e) Tumor size at the endpoint. (f) Histological characteristics of subcutaneous tumors (H&E staining) and immunohistochemical staining of NUTM1 protein (representing brd4-NUTM1 fusion protein) in mice treated with ARV-825 and PBS control.

(a)

(b)

(c)

(d)

(e)

(f)